Genetics and genomics of Sjgren's syndrome: Research provides clues to pathogenesis and novel therapies

Barbara M. Segal, Abu N M Nazmul-Hossain, Ketan Patel, Pamela Hughes, Kathy L. Moser, Nelson L. Rhodus

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Although the key inciting events that drive the progression from autoantibodies to clinical disease remain to be clarified, new light has been shed on the factors contributing to disease susceptibility and the role of genetic factors in determining Sjgren's syndrome (SS) disease phenotypes. The purpose of this article is to provide an update on the role of genetic markers in the susceptibility to and pathogenesis of SS. This article also discusses how genomic and proteomic technology can help in the design of specific therapeutics. Key findings: Recent evidence suggests that inflammatory genes associated with interferon pathways, and specific regulatory genes that control the maturation and proliferation of B cells, contribute to the pathogenesis of SS. Both gene expression profiling technology and gene association studies have been used to identify these key biological pathways. Molecularly, defined subsets of pSS patients are also being revealed by these studies. Previously, identified gene loci that predispose to multiple autoimmune disorders have been confirmed supporting the paradigm of "general" autoimmune disease genes. Association of SS with many additional susceptibility loci are likely to be established through ongoing genome-wide association scans (GWAS). Clues from genetic studies suggest that targeting B cells will prove to be an effective way of reducing the systemic manifestations of pSS and are supported by early clinical trials. Summary: Genome-wide technologies are likely to identify new genes and molecular pathways in the pathogenesis of SS that will be useful not only to identify patients at risk for SS, but also to identify subsets of patients at risk for variable levels of disease severity. In the future, these studies could identify novel biomarkers that will lead to significant advances in management by providing the means to tailor therapeutic strategies to individual patients.

Original languageEnglish (US)
Pages (from-to)673-680
Number of pages8
JournalOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
Volume111
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Genomics
Research
Genes
Technology
B-Lymphocytes
Therapeutics
Genome-Wide Association Study
Disease Susceptibility
Gene Expression Profiling
Regulator Genes
Genetic Markers
Autoantibodies
Proteomics
Interferons
Autoimmune Diseases
Biomarkers
Clinical Trials
Genome
Phenotype

Cite this

Genetics and genomics of Sjgren's syndrome : Research provides clues to pathogenesis and novel therapies. / Segal, Barbara M.; Nazmul-Hossain, Abu N M; Patel, Ketan; Hughes, Pamela; Moser, Kathy L.; Rhodus, Nelson L.

In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, Vol. 111, No. 6, 01.06.2011, p. 673-680.

Research output: Contribution to journalArticle

Segal, Barbara M. ; Nazmul-Hossain, Abu N M ; Patel, Ketan ; Hughes, Pamela ; Moser, Kathy L. ; Rhodus, Nelson L. / Genetics and genomics of Sjgren's syndrome : Research provides clues to pathogenesis and novel therapies. In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 2011 ; Vol. 111, No. 6. pp. 673-680.
@article{bb99665b329d4f719e13af290b68f78c,
title = "Genetics and genomics of Sjgren's syndrome: Research provides clues to pathogenesis and novel therapies",
abstract = "Purpose: Although the key inciting events that drive the progression from autoantibodies to clinical disease remain to be clarified, new light has been shed on the factors contributing to disease susceptibility and the role of genetic factors in determining Sjgren's syndrome (SS) disease phenotypes. The purpose of this article is to provide an update on the role of genetic markers in the susceptibility to and pathogenesis of SS. This article also discusses how genomic and proteomic technology can help in the design of specific therapeutics. Key findings: Recent evidence suggests that inflammatory genes associated with interferon pathways, and specific regulatory genes that control the maturation and proliferation of B cells, contribute to the pathogenesis of SS. Both gene expression profiling technology and gene association studies have been used to identify these key biological pathways. Molecularly, defined subsets of pSS patients are also being revealed by these studies. Previously, identified gene loci that predispose to multiple autoimmune disorders have been confirmed supporting the paradigm of {"}general{"} autoimmune disease genes. Association of SS with many additional susceptibility loci are likely to be established through ongoing genome-wide association scans (GWAS). Clues from genetic studies suggest that targeting B cells will prove to be an effective way of reducing the systemic manifestations of pSS and are supported by early clinical trials. Summary: Genome-wide technologies are likely to identify new genes and molecular pathways in the pathogenesis of SS that will be useful not only to identify patients at risk for SS, but also to identify subsets of patients at risk for variable levels of disease severity. In the future, these studies could identify novel biomarkers that will lead to significant advances in management by providing the means to tailor therapeutic strategies to individual patients.",
author = "Segal, {Barbara M.} and Nazmul-Hossain, {Abu N M} and Ketan Patel and Pamela Hughes and Moser, {Kathy L.} and Rhodus, {Nelson L.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.tripleo.2011.01.040",
language = "English (US)",
volume = "111",
pages = "673--680",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Genetics and genomics of Sjgren's syndrome

T2 - Research provides clues to pathogenesis and novel therapies

AU - Segal, Barbara M.

AU - Nazmul-Hossain, Abu N M

AU - Patel, Ketan

AU - Hughes, Pamela

AU - Moser, Kathy L.

AU - Rhodus, Nelson L.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Purpose: Although the key inciting events that drive the progression from autoantibodies to clinical disease remain to be clarified, new light has been shed on the factors contributing to disease susceptibility and the role of genetic factors in determining Sjgren's syndrome (SS) disease phenotypes. The purpose of this article is to provide an update on the role of genetic markers in the susceptibility to and pathogenesis of SS. This article also discusses how genomic and proteomic technology can help in the design of specific therapeutics. Key findings: Recent evidence suggests that inflammatory genes associated with interferon pathways, and specific regulatory genes that control the maturation and proliferation of B cells, contribute to the pathogenesis of SS. Both gene expression profiling technology and gene association studies have been used to identify these key biological pathways. Molecularly, defined subsets of pSS patients are also being revealed by these studies. Previously, identified gene loci that predispose to multiple autoimmune disorders have been confirmed supporting the paradigm of "general" autoimmune disease genes. Association of SS with many additional susceptibility loci are likely to be established through ongoing genome-wide association scans (GWAS). Clues from genetic studies suggest that targeting B cells will prove to be an effective way of reducing the systemic manifestations of pSS and are supported by early clinical trials. Summary: Genome-wide technologies are likely to identify new genes and molecular pathways in the pathogenesis of SS that will be useful not only to identify patients at risk for SS, but also to identify subsets of patients at risk for variable levels of disease severity. In the future, these studies could identify novel biomarkers that will lead to significant advances in management by providing the means to tailor therapeutic strategies to individual patients.

AB - Purpose: Although the key inciting events that drive the progression from autoantibodies to clinical disease remain to be clarified, new light has been shed on the factors contributing to disease susceptibility and the role of genetic factors in determining Sjgren's syndrome (SS) disease phenotypes. The purpose of this article is to provide an update on the role of genetic markers in the susceptibility to and pathogenesis of SS. This article also discusses how genomic and proteomic technology can help in the design of specific therapeutics. Key findings: Recent evidence suggests that inflammatory genes associated with interferon pathways, and specific regulatory genes that control the maturation and proliferation of B cells, contribute to the pathogenesis of SS. Both gene expression profiling technology and gene association studies have been used to identify these key biological pathways. Molecularly, defined subsets of pSS patients are also being revealed by these studies. Previously, identified gene loci that predispose to multiple autoimmune disorders have been confirmed supporting the paradigm of "general" autoimmune disease genes. Association of SS with many additional susceptibility loci are likely to be established through ongoing genome-wide association scans (GWAS). Clues from genetic studies suggest that targeting B cells will prove to be an effective way of reducing the systemic manifestations of pSS and are supported by early clinical trials. Summary: Genome-wide technologies are likely to identify new genes and molecular pathways in the pathogenesis of SS that will be useful not only to identify patients at risk for SS, but also to identify subsets of patients at risk for variable levels of disease severity. In the future, these studies could identify novel biomarkers that will lead to significant advances in management by providing the means to tailor therapeutic strategies to individual patients.

UR - http://www.scopus.com/inward/record.url?scp=79955890768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955890768&partnerID=8YFLogxK

U2 - 10.1016/j.tripleo.2011.01.040

DO - 10.1016/j.tripleo.2011.01.040

M3 - Article

VL - 111

SP - 673

EP - 680

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 6

ER -